Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Implexis
- ·The full record, as it builds
Funding rounds
No funding rounds for Implexis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Implexis
Developer of an automated drug formulation platform intended to accelerate pharmaceutical development through intelligent experimentation and optimisation. The company offers a platform that leverages proprietary automation to integrate pharmaceutical expertise with smart computational tools, enabling its clients to reduce time-to-market, minimise experimental costs, and identify optimal drug formulations faster and more efficiently.
- Sector
- Information Technology
- HQ
- London, United Kingdom
- Website
- implexis.ai/
- Ownership
- Privately Held (backing)
Implexis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Implexis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Implexis in its N-PORT filings yet. We sweep new filings monthly.